• A New Class of Therapy: Reinforcing Elenagen’s unique role in modulating chronic inflammation and reshaping the tumor microenvironment

As we move toward our US/Global Phase II/III trials, this external validation underscores the life‑saving potential of our platform.

The Path Forward:

We hope this recognition – alongside dozens of recent features in English, Spanish, and Portuguese – encourages future partners and investors to engage with the speed required to bring this potential breakthrough to clinicians and patients.”